How should I evaluate and manage a young man with low testosterone and inappropriately low follicle‑stimulating hormone (FSH) and luteinizing hormone (LH)?

Evaluation and Management of Young Men with Low Testosterone and Inappropriately Low FSH/LH

In a young man with low testosterone and inappropriately low or normal FSH/LH, you must pursue a comprehensive workup for secondary (hypogonadotropic) hypogonadism to identify potentially serious underlying causes including pituitary tumors, hyperprolactinemia, hemochromatosis, and genetic disorders before considering any treatment. 1

Initial Diagnostic Workup

Confirm the Diagnosis

• Repeat morning testosterone measurement (7-10 AM, fasting) to confirm persistent low testosterone (<300 ng/dL or <10.4 nmol/L) on at least two separate occasions 2, 3
• Measure free or bioavailable testosterone if conditions affecting SHBG are present (obesity, diabetes, medications) 1, 2
• Avoid testing during acute illness as this transiently suppresses testosterone 2

Essential Secondary Hypogonadism Evaluation

Once low testosterone with low/inappropriately normal LH and FSH is confirmed, the following tests are mandatory 1, 2, 1:

Required laboratory tests:

• Serum prolactin - to exclude prolactinoma or hyperprolactinemia
• Iron saturation/ferritin - to exclude hemochromatosis
• Other pituitary hormones (TSH, free T4, cortisol, IGF-1) - to assess for panhypopituitarism
• Morning cortisol - to evaluate adrenal function

Pituitary MRI is indicated if 2, 1:

• Severe secondary hypogonadism (testosterone <150 ng/dL)
• Panhypopituitarism is present
• Persistent hyperprolactinemia
• Symptoms/signs of mass effect (headache, visual changes, visual field defects)

Critical Reversible Causes to Exclude

Before labeling this as permanent hypogonadism, systematically evaluate for 1, 2, 3:

Medications and substances:

• Opioids (major cause)
• High-dose glucocorticoids
• Anabolic steroids
• Checkpoint inhibitors
• Medications causing hyperprolactinemia (antipsychotics, metoclopramide)

Medical conditions:

• Obesity (BMI ≥30) - affects 2-8% of men with secondary hypogonadism 3
• Obstructive sleep apnea
• Severe systemic illness
• Eating disorders
• Excessive exercise
• Nutritional deficiencies

Genetic/congenital causes in young men:

• Kallmann syndrome (anosmia, renal abnormalities, midline defects)
• Idiopathic hypogonadotropic hypogonadism
• Genetic disorders affecting gonadotropin secretion

Management Algorithm

If Reversible Causes Identified

First-line approach:

• Obesity-induced hypogonadism: Weight loss of ≥5% typically increases testosterone significantly and improves symptoms 4, 3
• Medication-induced: Discontinue or reduce offending agents if possible 3, 5
• Sleep apnea: Treat with CPAP
• Acute illness: Reassess after recovery 2

The guidelines explicitly prioritize addressing reversible causes over testosterone therapy 1, 4.

If Fertility is a Concern

Do NOT use testosterone therapy - it will suppress spermatogenesis and cause infertility 4, 6, 7

Instead, use gonadotropin therapy 4, 6:

• Human chorionic gonadotropin (hCG) alone or combined with FSH
• hCG stimulates testicular testosterone production and maintains spermatogenesis
• Recombinant and urinary-derived preparations are equally effective
• This is the standard treatment for secondary hypogonadism with fertility concerns 4, 8

Alternative for mild cases:

• Clomiphene citrate or enclomiphene may be considered for functional hypogonadism 9, 7
• Stimulates endogenous testosterone while preserving fertility
• Limited long-term data but shows promise in select patients

If Permanent Secondary Hypogonadism Without Fertility Concerns

Testosterone replacement therapy is appropriate when 1, 2, 5:

• Permanent hypothalamic/pituitary pathology confirmed
• Unable to discontinue causative medications
• Failed lifestyle interventions in obesity-related cases
• Patient has completed family or fertility not desired

Formulation selection (individualized based on preference, cost, convenience):

• Injectable testosterone (enanthate/cypionate)
• Transdermal gels
• Transdermal patches
• Buccal tablets
• Subcutaneous pellets

Critical Pitfalls to Avoid

1. Never diagnose hypogonadism on a single testosterone measurement - natural variation and transient suppression are common 1

2. Never start testosterone without excluding pituitary pathology - missing a pituitary tumor in a young man can have devastating consequences including vision loss 2, 1

3. Never give testosterone to men desiring fertility - it will suppress spermatogenesis; use gonadotropins instead 4, 6, 7

4. Never test during acute illness - this causes transient testosterone suppression and false-positive results 2

5. Never overlook obesity as the primary cause - weight loss should be first-line therapy, not testosterone 4, 3

6. Never ignore medication history - opioids and glucocorticoids are extremely common reversible causes 3, 5

Monitoring if Testosterone Therapy Initiated

• Testosterone levels at 3-6 months, then annually (target mid-normal range for young men)
• Hematocrit at 3-6 months, then annually
• Symptom assessment at each visit
• PSA and DRE at 3-12 months if prostate monitoring chosen 10

The key distinction in this young man is that secondary hypogonadism requires investigation for serious underlying pathology and has treatment options that preserve fertility, unlike primary testicular failure where testosterone replacement is the only option 1, 4.